DSIJ Mindshare

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

Ashwin Urkude 0 258 Article rating: 3.7

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

This pharma company stock went 8 per cent high, do you own it?

With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Kiran Shroff 0 1338 Article rating: 5.0

This pharma company stock went 8 per cent high, do you own it?                                                                                                                                                                                                       With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Heavy buying seen in these small-caps that hit fresh 52 week high on August 18!

On BSE, 265 stocks have hit their upper circuits whereas 131 stocks touched their lower circuits.  

Sayali Kotwal 0 5761 Article rating: 4.2

At 2.30 pm on Thursday, the markets were seen recovering from the day’s low as Asia- Pacific markets tumbled following the overnight cooling off of the most recent Wall Street rise.  

Lupin hit the ball out of the park! Is the tide turning in favour of the stock after this big announcement?

Karan Dsij 0 685 Article rating: 3.7

Another interesting point is that it’s not very usual these days to see pharma stock jumping 8-9 per cent but on Tuesday, Lupin broke this jinx as it soared nearly 9 per cent. Certainly, this might have brought a million-dollar smile to the faces of Lupin investors.  

RSS
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR